Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell Transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)

Vincent Mallet; Florian van Bömmel; Christopher Doerig; Sven Pischke; Olivier Hermine; Anna Locasciulli; Catherine Cordonnier; Thomas Berg; Darius Moradpour; Heiner Wedemeyer; Per Ljungman; ECIL-5

doi:10.1016/S1473-3099(16)00118-3

Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell Transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)

Standard

Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell Transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). / Mallet, Vincent; van Bömmel, Florian; Doerig, Christopher; Pischke, Sven; Hermine, Olivier; Locasciulli, Anna; Cordonnier, Catherine; Berg, Thomas; Moradpour, Darius; Wedemeyer, Heiner; Ljungman, Per; ECIL-5.

in: LANCET INFECT DIS, Jahrgang 16, Nr. 5, 05.2016, S. 606-17.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Mallet, V, van Bömmel, F, Doerig, C, Pischke, S, Hermine, O, Locasciulli, A, Cordonnier, C, Berg, T, Moradpour, D, Wedemeyer, H, Ljungman, P & ECIL-5 2016, 'Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell Transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)', LANCET INFECT DIS, Jg. 16, Nr. 5, S. 606-17. https://doi.org/10.1016/S1473-3099(16)00118-3

APA

Mallet, V., van Bömmel, F., Doerig, C., Pischke, S., Hermine, O., Locasciulli, A., Cordonnier, C., Berg, T., Moradpour, D., Wedemeyer, H., Ljungman, P., & ECIL-5 (2016). Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell Transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). LANCET INFECT DIS, 16(5), 606-17. https://doi.org/10.1016/S1473-3099(16)00118-3

Vancouver

Mallet V, van Bömmel F, Doerig C, Pischke S, Hermine O, Locasciulli A et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell Transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). LANCET INFECT DIS. 2016 Mai;16(5):606-17. https://doi.org/10.1016/S1473-3099(16)00118-3

Bibtex

@article{c9e9349a8fea41cf8b19530a22b95206,

title = "Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell Transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)",

abstract = "Viral hepatitis affects millions of people worldwide, and host immunity is the key determinant of patient outcome. Viral hepatitis can be life threatening in patients with haematological malignancy, including haemopoietic stem cell transplant recipients, because of the virus itself, or through a need to decrease the dose of chemotherapy. A past or currently infected haemopoietic stem cell donor could also transmit viral hepatitis. The burden of viral hepatitis in patients with haematological malignancies and the weak evidence on which previous guidelines are based has prompted the European Conference on Infection in Leukaemia (ECIL-5) to convene a group of experts in the fields of viral hepatitis and of haematological malignancy to specifically address previously unconsidered issues and grade the available quality of evidence according to the Infectious Diseases Society of America grading system. The group recommends that all patients should be screened for hepatotropic viruses before haematological treatment and that patients or haemopoietic stem cell donors with markers of past or current viral hepatitis should be assessed by an expert. Screening, vaccination, and treatment rules are reported in this Review.",

keywords = "Journal Article, Review",

author = "Vincent Mallet and {van B{\"o}mmel}, Florian and Christopher Doerig and Sven Pischke and Olivier Hermine and Anna Locasciulli and Catherine Cordonnier and Thomas Berg and Darius Moradpour and Heiner Wedemeyer and Per Ljungman and ECIL-5",

year = "2016",

month = may,

doi = "10.1016/S1473-3099(16)00118-3",

language = "English",

volume = "16",

pages = "606--17",

journal = "LANCET INFECT DIS",

issn = "1473-3099",

publisher = "Lancet Publishing Group",

number = "5",

}

RIS

TY - JOUR

T1 - Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell Transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)

AU - Mallet, Vincent

AU - van Bömmel, Florian

AU - Doerig, Christopher

AU - Pischke, Sven

AU - Hermine, Olivier

AU - Locasciulli, Anna

AU - Cordonnier, Catherine

AU - Berg, Thomas

AU - Moradpour, Darius

AU - Wedemeyer, Heiner

AU - Ljungman, Per

AU - ECIL-5

PY - 2016/5

Y1 - 2016/5

N2 - Viral hepatitis affects millions of people worldwide, and host immunity is the key determinant of patient outcome. Viral hepatitis can be life threatening in patients with haematological malignancy, including haemopoietic stem cell transplant recipients, because of the virus itself, or through a need to decrease the dose of chemotherapy. A past or currently infected haemopoietic stem cell donor could also transmit viral hepatitis. The burden of viral hepatitis in patients with haematological malignancies and the weak evidence on which previous guidelines are based has prompted the European Conference on Infection in Leukaemia (ECIL-5) to convene a group of experts in the fields of viral hepatitis and of haematological malignancy to specifically address previously unconsidered issues and grade the available quality of evidence according to the Infectious Diseases Society of America grading system. The group recommends that all patients should be screened for hepatotropic viruses before haematological treatment and that patients or haemopoietic stem cell donors with markers of past or current viral hepatitis should be assessed by an expert. Screening, vaccination, and treatment rules are reported in this Review.

AB - Viral hepatitis affects millions of people worldwide, and host immunity is the key determinant of patient outcome. Viral hepatitis can be life threatening in patients with haematological malignancy, including haemopoietic stem cell transplant recipients, because of the virus itself, or through a need to decrease the dose of chemotherapy. A past or currently infected haemopoietic stem cell donor could also transmit viral hepatitis. The burden of viral hepatitis in patients with haematological malignancies and the weak evidence on which previous guidelines are based has prompted the European Conference on Infection in Leukaemia (ECIL-5) to convene a group of experts in the fields of viral hepatitis and of haematological malignancy to specifically address previously unconsidered issues and grade the available quality of evidence according to the Infectious Diseases Society of America grading system. The group recommends that all patients should be screened for hepatotropic viruses before haematological treatment and that patients or haemopoietic stem cell donors with markers of past or current viral hepatitis should be assessed by an expert. Screening, vaccination, and treatment rules are reported in this Review.

KW - Journal Article

KW - Review

U2 - 10.1016/S1473-3099(16)00118-3

DO - 10.1016/S1473-3099(16)00118-3

M3 - SCORING: Journal article

C2 - 27599653

VL - 16

SP - 606

EP - 617

JO - LANCET INFECT DIS

JF - LANCET INFECT DIS

SN - 1473-3099

IS - 5

ER -